Breast-cancer prevention: Is the risk-benefit ratio in favour of tamoxifen?

Lancet

Volumn 362, Issue 9379, 2003, Pages 183-184

  Bergh, Jonas ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; RALOXIFENE; TAMOXIFEN;

BREAST CANCER; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER INVASION; CANCER PREVENTION; CANCER SURVIVAL; CARDIOVASCULAR EFFECT; CARDIOVASCULAR SYMPTOM; CLINICAL TRIAL; ETHNIC GROUP; HUMAN; LIFE EXPECTANCY; MAMMOGRAPHY; NOTE; OSTEOPOROSIS; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS;

EID: 0038445656     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)13951-7     Document Type: Note

References (13)

1. Schwartsmann G., Ratain M.J., Cragg G.M., et al. Anticancer drug discovery and development throughout the world. J Clin Oncol. 20:(suppl):2002;47S-59S.
2. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 351:1998;1451-1467.
3. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet. 352:1998;930-942.
4. Cuzick J., Forbes J., Edwards R., et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet. 360:2002;817-824.
5. Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 90:1998;1371-1388.
6. Cauley J.A., Norton L., Lippman M.E., et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial - multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat. 65:2001;125-134.
7. Veronesi U., Maisonneuve P., Sacchini V., Rotmensz N., Boyle P. Tamoxifen for breast cancer among hysterectomised women. Lancet. 359:2002;1122-1124.
8. Powles T., Eeles R., Ashley S., et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet. 352:1998;98-101.
9. Cuzick J., Powles T., Veronesi U., et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet. 361:2003;296-300.
10. Fisher B. National Surgical Adjuvant Breast and Bowel Project breast cancer prevention trial: a reflective commentary. J Clin Oncol. 17:1999;1632-1639.
11. Freedman A.N., Graubard B.I., Rao S.R., McCaskill-Stevens W., Ballard-Barbash R., Gail M.H. Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst. 95:2003;526-532.
12. Bergh J., Holmqvist M. Who should not receive adjuvant chemotherapy - international databases. J Natl Cancer Inst. 30:(suppl):2001;103-108.
13. Smith I.E., Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med. 348:2003;2431-2442.